AMRN:NSD-Amarin Corporation PLC (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 0.6042

Change

0.00 (0.00)%

Market Cap

USD 0.25B

Volume

0.71M

Analyst Target

USD 13.80
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland. Address: Iconic Offices, The Greenway, Dublin, Ireland, 112-114

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-28 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZN AstraZeneca PLC ADR

N/A

USD 241.92B
AMGN Amgen Inc

N/A

USD 173.38B
SNY Sanofi ADR

N/A

USD 144.83B
GILD Gilead Sciences Inc

N/A

USD 104.09B
BIIB Biogen Inc

N/A

USD 28.36B
GRFS Grifols SA ADR

N/A

USD 7.13B
MIRA MIRA Pharmaceuticals, Inc. Com..

N/A

USD 0.02B
SCLX Scilex Holding Company

N/A

N/A
SCLXW Scilex Holding Company

N/A

N/A

ETFs Containing AMRN

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 594.48% 100% F 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 594.48% 100% F 89% A-
Trailing 12 Months  
Capital Gain 556.74% 100% F 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 556.74% 100% F 89% A-
Trailing 5 Years  
Capital Gain -60.15% 43% F 19% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -60.15% 43% F 19% F
Average Annual (5 Year Horizon)  
Capital Gain -37.51% N/A N/A 6% D-
Dividend Return -37.51% N/A N/A 6% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 57.10% N/A N/A 31% F
Risk Adjusted Return -65.69% N/A N/A 14% F
Market Capitalization 0.25B 25% F 51% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.